Yves Pommier

USPTO Granted Patents = 36 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 162(Granted Patents)

Location History:

Rockville, MD (US) (2020)
Bethesda, MD (US) (1997 - 2024)

Company Filing History:

23 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

15 out of 2,660

Purdue Research Foundation

patents

2 out of 1,217

The United States of America As Represented by the Department of Health

patents

4. 1 out of 879

University of Kentucky Research Foundation

patents

5. 1 out of 12

Aronex Pharmaceuticals, Inc.

patents

6. 1 out of 101

Sun Yat-senuniversity

patents

7. 1 out of 2,308

University of Minnesota

patents

8. 1 out of 1

Second Military Medical University, Pla

patent

9. 1 out of 6

Provid Pharmaceuticals Inc.

patents

10. 4 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11999747 - Furoquinolinediones as inhibitors of TDP2 (2024-06-04),

2. 10906914 - Furoquinolinediones as inhibitors of TDP2 (2021-02-02),

3. 10875860 - Azaindenoisoquinoline compounds and uses thereof (2020-12-29),

4. 10759795 - Aza-A-ring indenoisoquinoline topoisomerase I poisons (2020-09-01),

5. 10617706 - Compounds for cancer chemotherapeutic sensitization (2020-04-14),

6. 10208035 - Compounds for inhibiting drug-resistant strains of HIV-1 integrase (2019-02-19),

7. 9676771 - Compounds for inhibiting drug-resistant strains of HIV-1 integrase (2017-06-13),

8. 9402842 - Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors (2016-08-02),

9. 9399660 - N-substituted indenoisoquinolines and syntheses thereof (2016-07-26),

10. 9388211 - N-substituted indenoisoquinolines and syntheses thereof (2016-07-12),

11. 9328073 - Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors (2016-05-03),

12. 9278089 - Method of treating HCV infection with a small molecule CHK2 inhibitor (2016-03-08),

13. 9217010 - N-substituted indenoisoquinolines and syntheses thereof (2015-12-22),

14. 9181193 - Indenoquinolone compound, preparation method and use thereof (2015-11-10),

15. 9175002 - Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors (2015-11-03),

Title: The Innovative Journey of Yves Pommier

Introduction: Yves Pommier is a renowned inventor based in Bethesda, MD, known for his groundbreaking contributions to the field of biomedicine and pharmaceuticals.

Latest Patents: Yves Pommier holds several patents in the areas of cancer research, molecular biology, and drug development, showcasing his continuous commitment to innovation.

Career Highlights: With a distinguished career spanning over three decades, Yves Pommier has worked tirelessly to pioneer novel treatments for cancer and other diseases. His research has led to the development of cutting-edge therapies that have significantly impacted the medical field.

Collaborations: Throughout his career, Yves Pommier has collaborated with leading scientists, researchers, and pharmaceutical companies to further his innovative projects. His collaborative efforts have resulted in the successful translation of his research into tangible solutions for patients worldwide.

Conclusion: Yves Pommier's relentless pursuit of innovation and his unwavering dedication to improving healthcare have solidified his position as a trailblazing inventor in the field of biomedicine. His work continues to inspire future generations of inventors and researchers to push the boundaries of what is possible in the realm of medical science.

This text is generated by artificial intelligence and may not be accurate.